Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Sell
37
ICUI Quote, Financials, Valuation and Earnings
Last price:
$149.94
Seasonality move
:
3.33%
Day range:
$147.93 - $150.35
52-week range:
$93.36 - $196.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.53x
P/B ratio:
1.87x
Volume:
159.5K
Avg. volume:
269.2K
1-year change:
52.72%
Market cap:
$3.7B
Revenue:
$2.4B
EPS (TTM):
-$4.83
Analysts' Opinion
-
Consensus RatingICU Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $190.00, ICU Medical has an estimated upside of 26.82% from its current price of $149.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $178.00 representing 100% downside risk from its current price of $149.82.
Fair Value
-
According to the consensus of 4 analysts, ICU Medical has 26.82% upside to fair value with a price target of $190.00 per share.
ICUI vs. S&P 500
-
Over the past 5 trading days, ICU Medical has underperformed the S&P 500 by -1.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ICU Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ICU Medical has grown year-over-year revenues for 3 quarters straight. In the most recent quarter ICU Medical reported revenues of $629.8M.
Earnings Growth
-
ICU Medical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ICU Medical reported earnings per share of -$0.97.
Enterprise value:
4.9B
EV / Invested capital:
1.39x
Price / LTM sales:
1.53x
EV / EBIT:
122.08x
EV / Revenue:
2.08x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
43.47x
Price / Operating cash flow:
32.10x
Enterprise value / EBITDA:
19.03x
Gross Profit (TTM):
$824.8M
Return On Assets:
-2.74%
Net Income Margin (TTM):
-4.94%
Return On Equity:
-5.75%
Return On Invested Capital:
-3.22%
Operating Margin:
7.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.3B | $2.3B | $2.4B | $587.9M | $629.8M | |
| Gross Profit | $697.8M | $739.9M | $824.8M | $171.6M | $227.3M | |
| Operating Income | -$3.6M | $47.8M | $97.4M | -$5.4M | $46.1M | |
| EBITDA | $191.5M | $253.2M | $260M | $47.2M | $87.4M | |
| Diluted EPS | -$3.12 | -$1.23 | -$4.83 | -$0.71 | -$0.97 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $920.8M | $1B | $1.2B | $1.2B | $1.4B | |
| Total Assets | $1.8B | $1.9B | $4.5B | $4.4B | $4.2B | |
| Current Liabilities | $195.5M | $200.8M | $494.6M | $481.8M | $556.2M | |
| Total Liabilities | $261.4M | $264.7M | $2.4B | $2.3B | $2.2B | |
| Total Equity | $1.5B | $1.6B | $2.1B | $2.1B | $2B | |
| Total Debt | -- | -- | $1.7B | $1.6B | $1.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.1M | $166.2M | $204M | $91.3M | $40.2M | |
| Cash From Investing | -$1.9B | -$87.9M | -$89M | -$30.7M | -$26.5M | |
| Cash From Financing | $1.6B | -$36M | -$55.8M | -$7.8M | -$8.2M | |
| Free Cash Flow | -$161.5M | $72.5M | $113.8M | $59.3M | $13.6M | |
ICUI
Sector
Market Cap
$3.7B
$39.2M
Price % of 52-Week High
76.34%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
52.72%
-38.63%
Beta (5-Year)
0.733
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$147.15
200-day SMA
Sell
Level
$154.23
Bollinger Bands (100)
Sell
Level
150.07 - 170.19
Chaikin Money Flow
Buy
Level
8.7M
20-day SMA
Buy
Level
$145.11
Relative Strength Index (RSI14)
Buy
Level
50.94
ADX Line
Sell
Level
32.94
Williams %R
Sell
Level
-12.409
50-day SMA
Sell
Level
$155.68
MACD (12, 26)
Sell
Level
-2.02
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
29.1M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.1007)
Sell
CA Score
(Annual)
Level (-0.3132)
Buy
Beneish M-Score
(Annual)
Level (-2.8084)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.4451)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Stock Forecast FAQ
In the current month, ICUI has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ICUI average analyst price target in the past 3 months is $190.00.
-
Where Will ICU Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that ICU Medical share price will rise to $190.00 per share over the next 12 months.
-
What Do Analysts Say About ICU Medical?
Analysts are divided on their view about ICU Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ICU Medical is a Sell and believe this share price will drop from its current level to $178.00.
-
What Is ICU Medical's Price Target?
The price target for ICU Medical over the next 1-year time period is forecast to be $190.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ICUI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ICU Medical is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ICUI?
You can purchase shares of ICU Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ICU Medical shares.
-
What Is The ICU Medical Share Price Today?
ICU Medical was last trading at $149.94 per share. This represents the most recent stock quote for ICU Medical. Yesterday, ICU Medical closed at $149.82 per share.
-
How To Buy ICU Medical Stock Online?
In order to purchase ICU Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is down 28.36% over the past day.
Buy
58
TNXP alert for Mar 25
Tonix Pharmaceuticals Holding [TNXP] is up 32.39% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 17.3% over the past day.
